Dss, INC 8-K filings

DSS, Inc. has entered into a securities purchase agreement with related party Alset, Inc. to raise $1,000,000 through a convertible promissory note and warrants.

DSS, Inc. has entered into a securities purchase agreement to receive a $2.45 million loan from Alset International Limited, a related party, in exchange for a convertible promissory note and warrants.

DSS, Inc. announced the closing of an underwritten public offering, raising approximately $0.7 million in net proceeds for general corporate and working capital needs.

DSS, Inc. announced that its stockholders approved the election of all director nominees, ratified the appointment of its independent auditor, and approved executive compensation on an advisory basis at its 2025 annual meeting.

DSS, Inc. has converted an outstanding $12 million revolving promissory note owed by Impact Biomedical Inc. into 31,939,778 shares of Impact Biomedical common stock, fully settling the debt.

DSS, Inc. has dismissed Grassi & Co., CPAs, P.C. and appointed HTL International, LLC. as its new independent registered public accounting firm, effective June 27, 2025, with no reported disagreements with the former auditor.

DSS Inc. awards one million shares of common stock to Heng Fai Holdings Limited, beneficially owned by director Heng Fai Ambrose Chan, as a bonus for services rendered.

DSS Inc. subsidiary, True Partner International Limited, invested $1 million in True Partner Capital Holding Limited, while DSS Inc. also sold 205,149 shares of its common stock for $200,000.

DSS, Inc. has entered into agreements to sell over one million shares of its common stock in a private placement, raising approximately $1 million for working capital and general corporate purposes.

DSS, Inc. successfully held its 2024 annual meeting, electing seven directors and ratifying its independent auditor.

DSS Inc. will restate its 2023 financial statements due to a $23.5 million overstatement of a loss related to the deconsolidation of Sharing Service Global Corporation.

DSS, Inc. has announced the resignation of its CEO, Frank Heuszel, effective August 23, 2024, and the appointment of Jason Grady as Interim CEO.

DSS, Inc. has announced that CEO Frank Heuszel will step down, with Jason Grady appointed as Interim CEO, effective August 23, 2024.

Sassuan Samson Lee has resigned from the Board of Directors of DSS Inc. effective immediately, with no indication of disagreement with the company's operations or policies.

DSS, Inc. has amended its loan agreement with Impact BioMedical, extending the maturity date to September 30, 2030, and increasing the principal balance to $12,859,328.60.